After months of speculation, TrumpRx is live and offering Americans a variety of important medications at most-favored-nation prices. 1 Or, more accurately, it’s providing coupons for certain ...

In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical ...

By giving small and mid-size biotechs access to real-world data and advanced analytics once reserved for large pharma, AI ...

FDA has approved Vybrique, the first oral film formulation of sildenafil for the treatment of erectile dysfunction, offering ...

Veradermics Inc., a late clinical-stage biopharmaceutical company focused on hair restoration, raised $256.3 million in an ...

Dave Carey, CEO, Preceptis Medical and Michael Monovoukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven ...

In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders ...

Novo Nordisk’s 2026 outlook reflects this shift with an adjusted basis excluding the non-recurring reversal of $4.2 billion in 340B Drug Pricing Program rebate provisions. 1 Sales and operating profit ...

Novartis’ fourth-quarter performance saw net sales decline 1% at constant currencies to $13.3 billion, a reflection of the accelerating impact of U.S. competition and revenue deduction adjustments, ...

The organization’s 2026 Breast Cancer Progress Outlook reflects the positive progress in early detection and awareness, showing that breast cancer mortality in the United States has declined 44% ...

In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application ...

Dave Carey, CEO, Preceptis Medical and Michael Manavukas, CEO, co-founder, AcuityMD note the importance of shifting ear tube procedures into the office, reducing anesthesia risk, and how AI-driven ...